IRADIMED (IRMD) CFO awarded 8,907 RSUs under 2023 equity plan

Rhea-AI Filing Summary

Iradimed Corp's chief financial officer John Glenn received a grant of 8,907 restricted stock units (RSUs). The RSUs were awarded under Iradimed Corporation's 2023 Equity Incentive Plan and convert into common stock on a one-for-one basis.

The award vests in three equal annual installments beginning on December 7, 2026. After vesting, Glenn will receive one share of common stock for each vested RSU, and he currently holds 8,907 RSUs directly following this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GLENN JOHN

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	8,907	$0.00	--

Holdings After Transaction: Restricted Stock Units — 8,907 shares (Direct)

Footnotes (1)

1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GLENN JOHN

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/03/2026		A		8,907		(2)	(2)	Common Stock	8,907	$0	8,907	D

Explanation of Responses:

1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

2. The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

	/s/ John Glenn	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRADIMED CORP (IRMD) report for John Glenn?

IRADIMED CORP reported that chief financial officer John Glenn received a grant of 8,907 restricted stock units. These RSUs were issued under the company’s 2023 Equity Incentive Plan as a stock-based compensation award, rather than an open-market purchase or sale of shares.

How many RSUs did IRMD’s CFO receive and how are they structured?

The CFO received 8,907 restricted stock units, each convertible into one share of common stock. All 8,907 RSUs are held directly and represent a stock-based incentive grant with no cash purchase price, reflecting long-term equity compensation rather than a market transaction.

When do John Glenn’s IRMD restricted stock units vest?

The RSUs vest in three equal annual installments beginning on December 7, 2026. Each year, one-third of the 8,907 units will vest, after which John Glenn will receive an equivalent number of IRADIMED common shares for the portion that has vested.

What happens to IRMD’s RSUs when they vest for the CFO?

When the RSUs vest, they convert into shares of IRADIMED common stock on a one-for-one basis. John Glenn will then receive the number of common shares equal to the vested RSUs, turning the stock units into actual share ownership over time.

Under which plan were the IRMD RSUs granted to the CFO?

The RSUs were granted under Iradimed Corporation's 2023 Equity Incentive Plan. This plan is used to provide stock-based compensation awards, aligning executive interests with shareholders by granting equity that converts into common stock as vesting conditions are satisfied.